Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study
Vanessa Selak,Rod Jackson,Katrina Poppe,Billy Wu,Matire Harwood,Corina Grey,Romana Pylypchuk,Suneela Mehta,Andrew Kerr,Sue Wells +9 more
TL;DR: The aim of this study was to take the next step and develop and validate multivariable prognostic models for bleeding risk among persons without CVD who were not treated with antiplatelet therapy.
Journal ArticleDOI
JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease.
Shintaro Nakano,Shun Kohsaka,Taishiro Chikamori,Kenji Fukushima,Yoshio Kobayashi,Ken Kozuma,Susumu Manabe,Hiroshi Matsuo,Masato Nakamura,Takayuki Ohno,Mitsuaki Sawano,Koichi Toda,Yasunori Ueda,Hiroyoshi Yokoi,Yodo Gatate,Tokuo Kasai,Yoshiaki Kawase,Naoya Matsumoto,Hiroshi Mori,Ryo Nakazato,Nozomi Niimi,Yuichi Sato,Ayumi Shintani,Ippei Watanabe,Yusuke Watanabe,Yuji Ikari,Masahiro Jinzaki,Masami Kosuge,K. Nakajima,Takeshi Kimura +29 more
Journal ArticleDOI
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
TL;DR: Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus - Analyses from the JPAD, POPADAD and AAA trials.
Journal ArticleDOI
Implementation Research: A Critical Component of Realizing the Benefits of Comparative Effectiveness Research
David C. Atkins,Joel Kupersmith +1 more
TL;DR: In this article, the authors draw on lessons from implementation research and their experience in the Veterans Administration (VA) healthcare system to offer recommendations about what is needed to support implementation of comparative effectiveness research (CER).
Journal ArticleDOI
Antiplatelet agents in clinical practice and their haemorrhagic risk.
TL;DR: Expanding knowledge on the mechanisms regulating the participation of platelets in haemostasis and thrombosis has led to great progress in antiplatelet therapy and may ultimately allow the bottleneck of current therapies to be overcome.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.